Tucatinib for Metastatic HER2+ Breast Cancer and Brain Metastases: Patient Selection

In clinically node-positive breast cancer, clipping of lymph nodes may induce higher rates of sentinel lymph node surgery after neoadjuvant chemotherapy.

Sarah Donahue, MPH, NP, speaks to the importance of communicating potential adverse effects associated with treatments such as CDK4/6 inhibitors to patients with breast cancer.

Those aged 18 to 40 years with invasive, HER2-positive breast cancer showed a survival benefit from upfront surgery over neoadjuvant chemotherapy.

Tucatinib plus trastuzumab emtansine shows a progression-free survival improvement in HER2-positive breast cancer in the phase 3 HER2CLIMB-02 trial, says Sara A. Hurvitz, MD, FACP.

Several presentations from the 41st Annual Miami Breast Cancer Conference focused on new and evolving data in the space, according to Neil M. Iyengar, MD.